BRCA1: a new genomic marker for non-small-cell lung cancer
Noemí Reguart1, Andrés Felipe Cardona, Esther Carrasco
1Medical Oncology Service, Catalan Institute of Oncology, ICO, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.
Abstract:
We are all aware of the recent rapid changes in cancer management mostly achieved with emerging new data regarding tumor biology. Currently, research in oncology is mainly focused on identifying the unique molecular characteristics of neoplasms and developing new targeted drugs to treat them. Although some tumors have specific genetic alterations that set off a cause-and-effect process after targeted treatment, those who work in the lung cancer field recognize that this is a more complex disease in which various genetic disorders carry its distinctive aggressiveness. At this time, the efforts of the scientific community are directed toward the identification of predictive markers to customize treatment based on specific genomic or protein expression profiles of individual tumors. This report provides a review on the breast cancer susceptibility gene 1, a promising gene determinant of response to different types of chemotherapy and its potential applications as a new molecular marker in lung cancer.
Insights
The breast cancer susceptibility gene 1 (BRCA1) shows promise as a predictive marker for lung cancer treatment response. Further research could personalize chemotherapy based on BRCA1
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cancer management is rapidly evolving, driven by advances in tumor biology and molecular profiling.
- Current oncology research focuses on identifying unique neoplastic characteristics and developing targeted therapies.
- Lung cancer is a complex disease where multiple genetic alterations contribute to its aggressiveness, necessitating predictive markers for personalized treatment.
Purpose of the Study:
- To review the role of the breast cancer susceptibility gene 1 (BRCA1) in cancer treatment.
- To explore the potential of BRCA1 as a predictive marker for chemotherapy response in lung cancer.
Main Methods:
- Literature review of studies on BRCA1 and its association with treatment response.
- Analysis of genomic and protein expression profiles related to BRCA1 in various cancers.
- Evaluation of current research on lung cancer genetics and targeted therapies.
Main Results:
- BRCA1 is implicated as a determinant of response to various chemotherapeutic agents.
- The study highlights the potential of BRCA1 as a novel molecular marker in lung cancer management.
- Customizing treatment based on specific tumor profiles, including BRCA1 status, is a key area of investigation.
Conclusions:
- BRCA1 holds significant promise as a predictive biomarker for optimizing lung cancer treatment strategies.
- Further investigation into BRCA1's role can lead to more personalized and effective chemotherapy regimens.
- Identifying molecular markers like BRCA1 is crucial for advancing precision oncology in lung cancer.
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:39lncRNA - Long Non-coding RNAs
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...